Global Health Data Gets Diversity Boost in Landmark Partnership

ZURICH, SWITZERLAND – February 05, 2026 – In a significant move to address the stark diversity gap in global medical research, healthcare data leader BC Platforms has announced a strategic partnership with OmicsBank, a specialist in AI-ready data infrastructure from emerging markets. The collaboration will integrate vast, multi-modal health datasets from over 12.5 million patients in India and the United Arab Emirates into BC Platforms' global network, which now surpasses 187 million patient lives.

This partnership aims to rectify a long-standing and critical bias in drug development and AI training, which has historically relied heavily on data from North American and European populations, limiting the effectiveness of precision medicine for a global audience.

Closing the Global Health Data Divide

For decades, the promise of precision medicine—therapies tailored to an individual's genetic makeup, lifestyle, and environment—has been hampered by a fundamental data problem. South Asian populations, which represent nearly 20% of the world's population, account for less than 2% of participants in global genome-wide association studies. This dramatic under-representation means that new drugs and diagnostic AI models are often developed and validated on a narrow subset of humanity, with findings that may not be generalizable or effective for billions of people.

The partnership between the Swiss-based BC Platforms and US-based OmicsBank directly confronts this challenge. By providing secure, research-ready access to longitudinal data from India and the UAE, the collaboration will enable life science companies to build more representative cohorts for clinical trials, conduct more accurate feasibility assessments, and develop therapies that are effective across diverse ethnic groups.

"India's population scale, disease diversity, and growing role in clinical research makes it invaluable from a scientific and regulatory perspective," said Mukhtar Ahmed, CEO of BC Platforms, in a statement. He emphasized the importance of this data for companies "seeking innovative targeted therapies and pursuing precision medicine strategies," adding that the partnership helps customers "better understand, develop and launch novel therapies supporting the unique needs of discrete patient populations around the world."

Unlocking New Frontiers for AI and Drug Discovery

The collaboration represents more than just an increase in patient numbers; it signifies a strategic shift towards the rich, untapped data reservoirs of emerging economies. India, with its genetic diversity and high burden of non-communicable diseases like cardiovascular disease, diabetes, and cancer, is a critical market for medical research. The data provided by OmicsBank is not only vast but also deeply detailed, or "multi-modal."

These datasets include millions of electronic medical records (EMRs), large-scale collections of digitized pathology slides, medical imaging, extensive genomic and proteomic sequencing data, and connected biospecimens. This level of detail is the essential fuel for training the next generation of sophisticated healthcare AI. By feeding algorithms with more diverse and complex information, researchers can develop more robust, less biased AI tools for everything from early cancer detection to predicting patient response to a specific drug.

"At OmicsBank, our focus has always been on building AI-ready data infrastructure that unlocks the full value of real-world and multi-omics data from emerging markets in a responsible and scalable way," stated Sumit Sinha, CEO of OmicsBank. "Partnering with BC Platforms allows us to extend this capability globally and help ensure that diverse patient populations are more accurately represented across the drug development lifecycle."

The venture is set for further expansion, with plans to incorporate additional datasets from Saudi Arabia, Taiwan, the Philippines, and Malaysia as OmicsBank grows its network of partner hospitals and diagnostic labs.

Navigating a Complex Web of Technology and Governance

Integrating such a massive and varied collection of data presents immense technical and ethical hurdles. The data arrives in different formats, from different systems, and is subject to stringent national privacy laws. Successfully harnessing it requires a sophisticated technological and legal framework.

The partnership addresses this through a multi-pronged approach. OmicsBank first transforms fragmented raw data into standardized, research-ready formats using its AI-powered infrastructure. The data is structured against global standards like the OMOP Common Data Model to ensure interoperability.

This harmonized data is then made accessible through BC Platforms' advanced technology stack. A key component is BC Mosaic, a federated trusted research environment. This federated architecture is a crucial innovation that allows researchers to run analyses on the data without it ever leaving its source hospital or country. Instead of pooling sensitive patient information in a central database, the analytical queries are sent to the data. This model is vital for complying with strict data localization laws, such as the UAE's Health Data Law, which generally prohibits patient data from being transferred abroad.

This technical solution is underpinned by a rigorous commitment to data governance. Both companies operate within a framework designed to comply with international regulations like GDPR and HIPAA, as well as local laws such as India's Digital Personal Data Protection Act of 2023. Through patent-pending anonymization techniques and meticulous tracking of patient consent, the partnership aims to build a system that is both powerful for research and trustworthy for patients and regulators.

By tackling the dual challenges of technological integration and ethical governance, the alliance between BC Platforms and OmicsBank is poised to unlock the immense potential of previously siloed health data. This initiative not only expands the map of medical research but also lays the groundwork for a future where healthcare innovations are more equitable, effective, and truly global in their reach.